Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Letairis
Synonyms :
ambrisentan
Class :
PAH, Endothelin Antagonists
Dosage Forms & Strengths
Tablet
5mg
10mg
Pulmonary Arterial Hypertension
5
mg
Orally
daily
w/wo tadalafil 20 mg PO qDay and after 4 weeks the dose of ambrisentan or tadalafil can be increased as PRN
Refer adult dosing
may enhance the serum concentration of cyclosporine
may decrease the therapeutic efficacy when used in combination
may increase the vasodilatory effect of phosphodiesterase 5 Inhibitors
May increase the vasodilatory effect when combined with Vasodilators
May increase the vasodilatory effect when combined with Vasodilators
May increase the vasodilatory effect when combined with Vasodilators
May increase the vasodilatory effect when combined with Vasodilators
May increase the vasodilatory effect when combined with Vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
may enhance the effect of vasodilators
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
Combining tegafur with ambrisentan can reduce tegafur’s metabolism
When ambrisentan is used together with fluconazole, this leads to reduction in the ambrisentan metabolism
When ambrisentan is used together with elbasvir, this leads to a rise in the concentration serum of elbasvir
When ambrisentan is used together with grazoprevir, this leads to a rise in the concentration serum of grazoprevir
When ambrisentan is used together with ouabain, this leads to reduction in ambrisentan excretion
the excretion of ambrisentan may be reduced when combined with cholecystokinin
ambrisentan: it may decrease activities of antihypertensive drugs
ambrisentan: it may decrease activities of antihypertensive drugs
ambrisentan: it may decrease activities of antihypertensive drugs
ambrisentan: it may decrease activities of antihypertensive drugs
ambrisentan: it may decrease activities of antihypertensive drugs
when both drugs are combined, there may be an increased level or effect of ambrisentan
it may increase the risk of adverse effects
may have an increased orthostatic hypotensive effect when combined with vasodilators
may have an increasingly adverse effect when combined with rosiglitazone
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
the rate of excretion of ambrisentan may be reduced
fostamatinib may increase the antihypertensive activities of ambrisentan
the hypotensive activity of ambrisentan may be increased
the metabolism of ambrisentan can be decreased when combined with oxycodone
Actions and Spectrum:
ambrisentan, a medication used to address pulmonary arterial hypertension (PAH), primarily operates by selectively inhibiting the activity of endothelin, a hormone. Its effects and range of actions can be summarized as follows:
Frequency defined
>10%
Headache
Peripheral edema
1-10%
Constipation
Dyspnea
Nasal congestion
Palpitations
Flushing
Abdominal pain
Nasopharyngitis
Sinusitis
Post marketing Reports
Anemia
Dizziness
Fatigue
Fluid retention
none
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Drug enters breast milk is unknown
Pregnancy Categories:
Patient Information Leaflet
Generic Name: ambrisentan
Why do we use ambrisentan?
ambrisentan is used to manage pulmonary arterial hypertension (PAH) in adult patients. Its mechanism of action involves reducing blood pressure in the lungs, which, in turn, aids the heart in pumping blood more effectively. This not only enhances the individual’s capacity for physical activity but also serves to prevent the progression of the condition.